BE in hepatic impairment? [BE/BA News]

posted by nobody – 2019-08-30 09:29  – Posting: # 20530
Views: 534

Hello again!

Today I have to read this here:

https://www.fdanews.com/articles/192544-persion-petitions-fda-to-raise-the-safety-bar-for-extended-release-opioid

But the originator found differences in PK in mild/moderate hepatic impairment not worth any dose adjustment according to the current label and the differences as outlined in the FDA AssRep are unimpressive. I'm trying to figure out a formulation-related influence of hepatic function on BA/BE...

Lawyers looking for some work? How low can you go? Is that state-of-the-art in 2019?

Kindest regards, nobody

Complete thread:

Activity
 Admin contact
20,343 posts in 4,272 threads, 1,401 registered users;
online 4 (1 registered, 3 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 21:59 CET

Every man gets a narrower and narrower field of knowledge
in which he must be an expert in order to compete with other people.
The specialist knows more and more about less and less
and finally knows everything about nothing.    Konrad Lorenz

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5